Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture

What Was Tested

Researchers studied Abaloparatide in the context of osteoporosis and bone density in this randomized controlled trial publication.

Current treatment guidelines recommend treatment for postmenopausal women with a T score <2.5 regardless of age.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, women only.

Subgroup analysis of women in the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial who were <65 years old and met modified utilization management criteria (baseline T score ≤-2.5 [any site] and ≥1 prevalent vertebral and/or ≥1 prior clinical fracture within 5 years of randomization).

How the Study Was Run

In design terms this was a randomized and double-blind study.

The participants were allocated by chance, so the Abaloparatide group and the comparison group should start out alike.

As a double-blind Abaloparatide study, the assignments were hidden from both participants and investigators until the end.

The methods mention a period of 5 years.

What Was Measured

PubMed files the paper under topics including Bone Density, Bone Density Conservation Agents, Incidence, Osteoporosis, Postmenopausal, Osteoporotic Fractures, Parathyroid Hormone-Related Protein and Postmenopause.

The authors tagged it with the keywords abaloparatide, nonvertebral fracture, number needed to treat and vertebral fracture.

What This Means in Plain Language

The paper is a randomized and double-blind study of Abaloparatide in people with osteoporosis and bone density over 5 years.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Clinical therapeutics), a journal based in United States.

More context: the Abaloparatide compound page, Osteoporosis and bone density research.